Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Castagna

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|July 19, 2016
The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamideA Rimondo, R Crocchiolo, J El-Cheikh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2016
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationS Genadieva-Stavrik, A Boumendil, P Dreger, et al.
Leukemia|May 6, 2016
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantationS Dietrich, H Finel, C Martinez, et al.
Bone Marrow Transplantation|September 16, 2014
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomasL Castagna, S Bramanti, S Furst, et al.
Bone Marrow Transplantation|December 13, 2016
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AMLF Legrand, A-C Le Floch, A Granata, et al.
Bone Marrow Transplantation|November 10, 2015
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromesR Devillier, S Bramanti, S Fürst, et al.
Bone Marrow Transplantation|August 16, 2016
Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysisP V O'Donnell, M Eapen, M M Horowitz, et al.
Bone Marrow Transplantation|March 3, 2016
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamideL Castagna, S Bramanti, S Furst, et al.
Bone Marrow Transplantation|October 18, 2016
Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantationL Castagna, B Sarina, R Crocchiolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†S P Robinson, A Boumendil, H Finel, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|July 19, 2016
The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamideA Rimondo, R Crocchiolo, J El-Cheikh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2016
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationS Genadieva-Stavrik, A Boumendil, P Dreger, et al.
Leukemia|May 6, 2016
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantationS Dietrich, H Finel, C Martinez, et al.
Bone Marrow Transplantation|September 16, 2014
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomasL Castagna, S Bramanti, S Furst, et al.
Bone Marrow Transplantation|December 13, 2016
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AMLF Legrand, A-C Le Floch, A Granata, et al.
Bone Marrow Transplantation|November 10, 2015
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromesR Devillier, S Bramanti, S Fürst, et al.
Bone Marrow Transplantation|August 16, 2016
Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysisP V O'Donnell, M Eapen, M M Horowitz, et al.
Bone Marrow Transplantation|March 3, 2016
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamideL Castagna, S Bramanti, S Furst, et al.
Bone Marrow Transplantation|October 18, 2016
Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantationL Castagna, B Sarina, R Crocchiolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†S P Robinson, A Boumendil, H Finel, et al.
Pageof 10